Skip to content

Precision Application of Next-Generation Sequencing in Solid Tumors and Infectious Diseases

Precision Application of Next-Generation Sequencing in Solid Tumors and Infectious Diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110500
Enrollment
Unknown
Registered
2025-10-14
Start date
2025-10-15
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors

Interventions

Gold Standard:For tumor samples??, the reference standard in this study is a comprehensive assessment based on ??histopathological diagnosis?? of surgically resected or biopsied specimens, combined wi
Index test:The index tests in this study primarily include optimized multi-gene and pan-cancer NGS detection panels with a machine learning-based mutation interpretation model for solid tumors, as wel

Sponsors

Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Solid Tumor Patients:?? Age over 18 years; underwent tumor resection surgery at our hospital, with tissue samples stored in our institution for = 2 ml, and infected tissue sample weight >= 50 mg; availability of comprehensive clinical and pathological information.

Exclusion criteria

Exclusion criteria: 1. Oncology-related exclusions:?? Patients with metastatic cancer of unknown primary origin; history of previous malignancy; any form of anticancer therapy prior to surgery, including radiotherapy, chemotherapy, neoadjuvant therapy, or immunotherapy; tissue samples archived for >5 years or with tumor content 99%; cases of mixed infection with >= 4 distinct pathogen species identified; recipients of organ transplants or prior allogeneic bone marrow or stem cell transplantation; samples with positive blood culture results but no other evidence of localized infection; any other clinically significant condition deemed by the investigator to make the patient unsuitable for participation in this clinical study.

Design outcomes

Primary

MeasureTime frame
Overall Agreement;Sensitivity;

Secondary

MeasureTime frame
Specificity;Limit of Detection;

Countries

China

Contacts

Public ContactYu Zhou

Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China

zhouyu422@yahoo.com+86 181 4020 7009

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026